Extended half-life (EHL) recombinant factor VIII drugs promise excellent prophylaxis by reducing dose frequency, enhancing compliance, and improving quality of life while maintaining safety and efficacy. This session will provide a detailed overview of the rationale for developing EHL coagulation factors and their use in the treatment of haemophilia A, with a focus on the indications, efficacy, and safety of the existing EHL-FVIII products.

Emerging role of EHL FVIII in Hemophilia A Mx with better clinical outcomes

In India, hemophilia goes undiagnosed because of a lack of awareness and poor public infrastructure for detection. Roche, a global leader in the pharmaceutical industry, will take you through the broad classification of the condition, its clinical presentations, and the coagulation cascade underlying the process of clotting. Additionally, the session aims to cover the clinical interpretation of PT, aPTT, and TT and provide a detailed overview of Hemophilia A, from prevention to treatment. Join us live and exclusive on Medflix for this fascinating session!

Your Practice & Hemophilia

Advisor for Hemophilia, Govt. of NCT Delhi and Medical Consultant, Maulana Azad Medical College, New Delhi

Naresh Gupta

3

939

16.3k

4.6

Sessions Taken

206

4.6

377

4.6